Biotech CEOs: Can Scientist-Founders Remain In Charge?

A New Breed Of Scientist-Founder: PhD-Carrying Entrepreneurs Who Want To Translate Their Ideas Into Companies

Founder-CEOs do not typically remain at the helm as biotechs mature. Exceptions to that rule are multiplying, though, especially in Europe as companies aim directly for Nasdaq.

Captain
When do scientific founders stay at the helm of their biotech businesses? • Source: Shutterstock

There are several high-profile examples of biotech leaders who have seeded, nurtured and grown their companies into profitable, sustainable organisations. Josh Boger founded Vertex Pharmaceuticals Inc. in 1989 and was CEO for twenty years, building a $43bn behemoth. Jean-Paul Clozel, with wife Martine and two co-founders, built Actelion Pharmaceuticals Ltd. into Europe’s largest, most successful biotech, finally succumbing to a $30bn offer from Johnson & Johnson in 2017. Art Levinson – not a founder, but a very early employee at Genentech Inc. – was promoted from R&D chief to CEO in 1995, defying skeptics to build the industry leader. The message from these success stories: science rules, not just at the start, but all the way.

These individuals are exceptional, however. Few combine the broad skill set (and dogged perseverance) required to discover and fund a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from C-Suite Speaks

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success. 

More from Leadership

Rising Leaders 2025: Neha Krishnamohan On Readying For Uncertainty In Biotech

 

Neha Krishnamohan, CFO of Artiva Biotherapeutics, brings Wall Street precision to biotech innovation, helping lead the company through a successful IPO while advancing NK cell therapies for cancer and autoimmune diseases.

Rising Leaders 2025: J&J’s June Lanoue On Working With A Cure In Mind

 
• By 

As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy